|
Gene: ZNF275 |
Gene summary for ZNF275 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ZNF275 | Gene ID | 10838 |
Gene name | zinc finger protein 275 | |
Gene Alias | ZNF275 | |
Cytomap | Xq28 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A6NFS0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10838 | ZNF275 | HCC1_Meng | Human | Liver | HCC | 5.33e-39 | 8.40e-02 | 0.0246 |
10838 | ZNF275 | HCC2_Meng | Human | Liver | HCC | 1.18e-15 | 1.39e-01 | 0.0107 |
10838 | ZNF275 | HCC2 | Human | Liver | HCC | 7.25e-05 | 3.01e+00 | 0.5341 |
10838 | ZNF275 | S027 | Human | Liver | HCC | 8.20e-08 | 8.23e-01 | 0.2446 |
10838 | ZNF275 | S028 | Human | Liver | HCC | 8.54e-23 | 8.12e-01 | 0.2503 |
10838 | ZNF275 | S029 | Human | Liver | HCC | 3.50e-19 | 8.25e-01 | 0.2581 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 3 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF275 | SNV | Missense_Mutation | rs782808492 | c.104N>T | p.Ser35Leu | p.S35L | protein_coding | tolerated(0.17) | benign(0) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ZNF275 | SNV | Missense_Mutation | rs782477245 | c.406N>G | p.Lys136Glu | p.K136E | protein_coding | deleterious(0.03) | benign(0.019) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD | |
ZNF275 | SNV | Missense_Mutation | novel | c.649N>A | p.Ser217Thr | p.S217T | protein_coding | tolerated(0.09) | benign(0.047) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD | |
ZNF275 | SNV | Missense_Mutation | novel | c.618N>T | p.Glu206Asp | p.E206D | protein_coding | tolerated(0.07) | benign(0.003) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD | |
ZNF275 | SNV | Missense_Mutation | rs782364790 | c.746G>A | p.Arg249His | p.R249H | protein_coding | tolerated(0.15) | benign(0.007) | TCGA-AX-A2HJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ZNF275 | SNV | Missense_Mutation | c.553N>A | p.Glu185Lys | p.E185K | protein_coding | deleterious(0.01) | possibly_damaging(0.751) | TCGA-AX-A3G7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
ZNF275 | SNV | Missense_Mutation | novel | c.475G>A | p.Gly159Ser | p.G159S | protein_coding | deleterious(0.03) | benign(0.27) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZNF275 | SNV | Missense_Mutation | rs781856747 | c.544G>A | p.Glu182Lys | p.E182K | protein_coding | tolerated(0.06) | benign(0.013) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ZNF275 | SNV | Missense_Mutation | novel | c.584N>A | p.Gly195Asp | p.G195D | protein_coding | tolerated(0.21) | benign(0.372) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ZNF275 | SNV | Missense_Mutation | c.670C>A | p.Leu224Ile | p.L224I | protein_coding | deleterious(0.01) | possibly_damaging(0.537) | TCGA-BS-A0TE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |